- 29-11-2019BackgroundSeveral international pediatric guidelines for treatment of Differentiated Thyroid Cancer (DTC) exist. However discordances among these guidelines exist. Furthermore, no…
- 29-11-2019IntroductionChildhood brain tumor survivors (CBTS) are at increased risk for developing obesity which may negatively influence cardiometabolic health in adulthood.…
- 29-11-2019AbstractPurpose: Recently, the management of patients with low-risk differentiated non-medullary thyroid cancer (DTC), has been critically appraised, questioning whether these…
- 27-11-2019Background Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different…
- 27-11-2019Background: Trans women can receive gender-affirming hormone treatment (HT) to induce feminization including breast growth. Previous studies showed modest breast…
- 27-11-2019Background: Gender-affirming hormone treatment in transgender people potentially has side effects, such as cardiovascular disease and cancer, with a potential…
- 27-11-2019Introduction/backgroundPatients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) have limited treatment options. Since expression of somatostatin receptors and uptake on somatostatin…
- 27-11-2019Background: Early-onset obesity is associated with genetic obesity. According to the Endocrine Society guideline, genetic screening is indicated in selected…
- 26-11-2019Background: 18F-FDG PET/CT is useful for localising metastatic pheochromocytoma and paragangliomas (PPGLs). In other cancers 18F-FDG PET/CT is used for therapy…
- 26-11-2019Metastatic castration-resistant prostate cancer (CRPC) remains a clinical challenge despite antitumoral therapies such as taxane chemotherapeutics, enzalutamide, and abiraterone acetate.…
